

Attorney Docket No. P67671US0
Application No.: 10/069,128

BEST AVAILABLE COPY

Amendments to the specification:

Replace page 4, line 15, through page 5, line 11, with:

For the synthesis of the peptides with the following sequences:

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (SEQ ID NO: 1) (ANP/CDD)

Ser-Phe-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (SEQ ID NO: 2) (BNP)

Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (SEQ ID NO: 3) (CNP)

Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (SEQ ID NO: 4) (urodilatin), 1

the continuous flow method (Atherton and Sheppard, in "Solid Phase Peptide Synthesis, IRL Press, Oxford 1989) has been used. The peptide sequence mentioned is synthesized by means of an automated peptide synthesis apparatus (Minigen 9050) using Fmoc amino acids. The Fmoc amino acids had L-configuration and were employed in a fourfold excess.